Description
Variational AI is at the forefront of early-stage drug discovery, leveraging advanced generative AI to identify and design novel, drug-like small molecules. Their proprietary Enki™ platform is engineered to generate optimized, synthesis-ready compounds that are tailored to specific target product profiles. This innovative approach aims to redefine the economics of drug discovery by significantly reducing the time and cost associated with traditional methods.
Read More
The Enki™ platform addresses the vastness of chemical space, estimated at 10⁶⁰ possible drug-like molecules, by moving beyond the limitations of conventional screening libraries. Instead of starting with known compounds, Enki™ generates entirely new molecular structures de novo. This allows R&D teams to explore uncharted chemical territories and discover first- and best-in-class compounds. The platform is purpose-built for early-stage drug discovery, covering 873 pre-trained drug targets across various key classes, including kinases, GPCRs, and proteases.
Variational AI's process begins with defining the preclinical target product profile (TPP), specifying on/off-targets and desired physico-chemical properties as input for the Enki™ AI. The platform then generates a diverse set of novel structures that meet these defined criteria. Partners can select compounds for synthesis and testing, or utilize Enki™ for hyper-efficient lead optimization, even when constrained to a specific scaffold. This multiparameter optimization capability allows for simultaneous refinement across over 50 parameters, including potency, selectivity, toxicity, ADMET properties, pharmacokinetics, and synthetic accessibility.
The company's mission is to transform early drug discovery through generative AI, driven by a cross-disciplinary team of machine learning researchers, chemists, and biotech professionals. By providing higher-quality leads and reducing costly iterations, Variational AI aims to accelerate timelines and increase the probability of success for drug development programs, ultimately benefiting patients who need new therapeutics. Their collaborations with biopharmaceutical partners span various disease areas, underscoring their commitment to positively impacting lives through scientific innovation.
- CategoryScientific Discovery & Lab Tools
- Pricing ModelContact sales
- DeploymentCloud
- PlatformsWeb
Variational AI's Core Features
Generative AI platform for drug discovery
Enki™ platform for compound generation
Optimizes for potency, selectivity, ADMET, and synthetic feasibility
Generates novel, synthesis-ready, lead-like compounds
Bypasses hit identification and hit-to-lead stages
Enables direct move to Lead Optimization
Covers 873 pre-trained drug targets
Simultaneous optimization across 50+ parameters
De novo molecular structure generation
Hyper-efficient lead optimization capabilities
Tailored to specific target product profiles
How to use Variational AI?
Define Target Product Profile: Specify on/off-targets and physico-chemical properties.
Enki™ Generates Compounds: The AI designs novel, diverse structures meeting the TPP.
Select Compounds: Choose molecules for synthesis and testing.
Lead Optimization: Utilize Enki™ for hyper-efficient optimization if needed.
Variational AI's Use Cases
- Novel Compound Design
- Lead Optimization
- Targeted Drug Discovery
- Exploring Chemical Space
- Therapeutic Development
- De Novo Synthesis Planning
